Abstract 829
Background
there is little solid evidence of the effectiveness of psychological interventions using MBRS program for those with advanced cancer. The objective of this study was to evaluate the acceptability and potential benefits of MBSR for pt with cancer pain in early palliative care.
Methods
Main inclusion criteria were: advanced cancer pt in early palliative care; NRS >3;PS >60% according to Karnosky, informed consent. 20 advanced cancer pt were enrolled. Each session included different forms of mindfulness meditation practice, mindful awareness during yoga postures and mindfulness during stressful situations. Participants enter upon enrolling into a commitment to carry out daily 45-min homework assignments .A dedicate nurse with experience in palliative care attended each mindfulness session. Primary outcome was total pain at the end of MBSR intervention evaluated by both VAS and ESAS scales. Secondary outcome was mood state change evaluated by POMS questionnaire. Satisfaction of treatment and compliance were also evaluated. All questionnaires along with a form for collecting personal and clinical data were administered by nurse at baseline and at the end of MBSR intervention.
Results
19 out of 20 were female with median age 54 years old. 56% were receiving morphine for cancer pain. Preliminary results did show slight reduction in total pain score which however was not statistically significant. The POMS test showed significant changes in the mean scores indicating a statistically significant improvement of mood at the end of mindfulness sessions. Compliance program and homework was 70% while pt satisfaction was 78%.
Conclusions
This program appears to be feasible and well accepted. The improvements in the mood state suggests that the mindfulness techniques could play a role in helping patients to reduce mood disturbance. The role of nurse was optimal to allow critically ill patients to participate in MBRS and to guarantee adherence and satisfaction. Moreover nurse was very helful to support the mindfulness trainer in managing cancer patients according to their physical needs. Finally the presence of nurse has been evaluated by patients as part of cancer caring.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fabrizio Artioli.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract